KIR2DL1 killer cell immunoglobulin like receptor, two Ig domains and long cytoplasmic tail 1
ENSG00000125498 · protein coding · Open Targets profile
Receptor on natural killer (NK) cells for some HLA-C alleles such as w4 and w6. Inhibits the activity of NK cells thus preventing cell lysis. .
Each band is a group of drugs. It runs from the kind of drug on the left to the furthest stage that drug has reached in any disease on the right. Thicker bands mean more drugs.
Approved bands are highlighted. Withdrawn means the drug was pulled from the market or from development. A combined phase counts as the later one (Phase 1/2 is shown as Phase 2). Hover a band for the drug names. Source: Open Targets Platform, fetched live.
Each row is a cancer, strongest overall evidence first. The two dots show how strong the inherited (germline) and tumour-mutation (somatic) evidence is; the line between them is the gap.
Scores run from 0 (no evidence) to 1 (strongest). A missing dot at 0 means Open Targets holds no evidence of that kind. Source: Open Targets Platform, fetched live.
Tractability
- Antibody
- Advanced Clinical, UniProt loc high conf, GO CC high conf, UniProt SigP or TMHMM
gnomAD loss of function constraint: o/e 1.1197999715805054 (upper bound 1.4678000211715698). Low values mean loss of function is poorly tolerated, a safety flag for inhibition.
Who runs trials of these drugs
Principal investigators and study chairs on 5 registry trials, updated in the last three years, of the most advanced drugs against KIR2DL1 (IPH-2101, lirilumab), ranked by Phase 2+ trials. Live from ClinicalTrials.gov.
- Birgit GeoergerGustave Roussy, Cancer Campus, Grand Paris · 1 of 1 trials Phase 2+
- Glenn J. HannaDana-Farber Cancer Institute · 1 of 1 trials Phase 2+
- Nikhil MunshiDana-Farber Cancer Institute- Medical Oncology- Boston MA-USA · 1 of 1 trials Phase 2+
- Petros GrivasUniversity of Washington · 0 of 1 trials Phase 2+
Registry trials of IPH-2101, lirilumab updated in the last three years, counted by the country group of their listed sites. A trial with sites in several groups counts in each; 3 of 5 have all sites in one country.
Site counts are not patients per country, and trials registered only outside ClinicalTrials.gov are not covered. Where sites are is a fact about the record, not a judgement of its quality. Europe is the EU and EEA, the UK and Switzerland. Source: ClinicalTrials.gov, fetched live.
4 trials of drugs against KIR2DL1 were stopped early
Terminated, withdrawn and suspended interventional trials of IPH-2101, lirilumab, newest update first, live from ClinicalTrials.gov. Each reason is quoted exactly as the registry gives it; we do not sort reasons into safety, efficacy or business. Dates are the last registry update. Showing the 4 most recent of 4.
- terminated · 2022-02-28 · Incyte Corporation · Lirilumab“A business decision made by Incyte after analysis of data from a sister study.”
- terminated · 2020-01-14 · M.D. Anderson Cancer Center · Lirilumab“Enrollment was stopped after the sponsor's decision not to pursue the development of lirilumab for myeloid malignancies.”
- terminated · 2019-11-19 · National Cancer Institute (NCI) · matched by the registry's drug synonyms“Lack of patients meeting the defined primary obj. (50% decline in M-protein).”
- terminated · 2019-09-24 · M.D. Anderson Cancer Center · Lirilumab“This study was terminated early due to response rates not meeting the anticipated minimum of 30%.”
Paediatric incentives and obligations for KIR2DL1's drugs
For IPH-2101, lirilumab: what EMA and FDA publish about paediatric plans, orphan status and pediatric approvals, and how many registered studies take children. Each line is a yes, no or not published fact from the record linked under it; none of it is a forecast.
- FDA pediatric target list: no · KIR2DL1 is not on the listRule: Target is on FDA's Pediatric Molecular Target List (relevant targets). Source: FDA Pediatric Molecular Target List (Listed as February 2026 on the FDA Pediatric Oncology page; the file served is 9.7.22_the_relevant_molecular_target_list.xlsx, whose Summary of Changes sheet is headed 'SEPTEMBER 2022 UPDATE' (footnote date 2022-09-01)), 2026-11-11
- EU paediatric investigation plan: no · No EMA paediatric investigation plan decision names iph-2101, lirilumabRule: An EMA PIP decision (agreement, modification or waiver) lists the drug as its active substance, exact name. Source: EMA data download (dated snapshot), 2026-11-11
- EU orphan designation: no · No EU orphan designation names iph-2101, lirilumabRule: An EU orphan designation lists the drug as its active substance (exact name) or belongs to a medicine that does; withdrawn and expired designations are listed with their status. Source: EMA data download (dated snapshot), 2026-11-11
- Authorised in the EU: no · EMA lists no centrally authorised medicine of iph-2101, lirilumabRule: An EMA medicine record lists the drug as its active substance or INN, exact name; national-only authorisations are not in this file. Source: EMA data download (dated snapshot), 2026-11-11
- FDA orphan designation: not published · FDA's orphan designation database turns away automated requests, so this app does not read it; search it by hand at the linkRule: Would be: an FDA orphan designation names the drug. Source: FDA orphan designations search
- FDA pediatric oncology approval: no · FDA's table lists no pediatric approval of iph-2101, lirilumabRule: FDA's Pediatric Oncology Drug Approvals table names the drug. Source: FDA Pediatric Oncology Drug Approvals (content current as of 2026-03-03), 2026-11-12
- Registered studies open to children: yes · 1 interventional studies of iph-2101, lirilumab include patients under 18; 1 is recruiting, not yet recruiting or activeRule: The registry's age group includes Child (birth to 17 years), which also counts studies that set no minimum age. Source: ClinicalTrials.gov search, 2026-11-12
Rare pediatric disease voucher. FDA, content current as of 29 Apr 2026: “As of February 3, 2026, enactment of the Consolidated Appropriations Act, 2026, the rare pediatric disease PRV program will sunset after September 30, 2029. FDA may not award any PRVs under this program after September 30, 2029.” Voucher sale prices are not shown here; they appear only as company-reported news. FDA: Rare Pediatric Disease Designation and Priority Review Voucher Programs
All 2 drugs and clinical candidates as a table
Each drug, stage and indication links to its Open Targets record, where the trials and approvals behind it are listed. Salt forms (for example a mesylate) are listed as Open Targets records them, as separate entries.
| Drug | Type | Highest stage | Indications | Source records |
|---|---|---|---|---|
| IPH-2101 | Unknown | phase 2 | plasma cell myeloma, acute myeloid leukemia | Open Targets · ChEMBL |
| LIRILUMAB | Antibody | phase 2 | acute myeloid leukemia by FAB classification, myelodysplastic syndrome, acute myeloid leukemia, B-cell chronic lymphocytic leukemia, head and neck squamous cell carcinoma, Hodgkins lymphoma, plasma cell myeloma, glioma, +2 more | Open Targets · ChEMBL |